Benign Prostatic Hyperplasia Drugs Market

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Benign Prostatic Hyperplasia Drugs Market contains market size and forecasts of Benign Prostatic Hyperplasia (BPH) Drugs in global, including the following market information:

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Sales, 2017-2022, 2023-2028, (M Units)

Global top five Benign Prostatic Hyperplasia (BPH) Drugs companies in 2021 (%)

The global Benign Prostatic Hyperplasia (BPH) Drugs market was valued at 3425.9 million in 2021 and is projected to reach US$ 4258.9 million by 2028, at a CAGR of 3.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Alpha-Blocker Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Mylan, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment Percentages, by Type, 2021 (%)

• Alpha-Blocker
• Phosphodiesterase Type-5 Inhibitors
• Others

Global Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Drugstores
• Others

Global Benign Prostatic Hyperplasia (BPH) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Benign Prostatic Hyperplasia (BPH) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Benign Prostatic Hyperplasia (BPH) Drugs revenues share in global market, 2021 (%)
• Key companies Benign Prostatic Hyperplasia (BPH) Drugs sales in global market, 2017-2022 (Estimated), (M Units)
• Key companies Benign Prostatic Hyperplasia (BPH) Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Eli Lilly
• GlaxoSmithKline
• Astellas Pharma
• Sanofi
• Pfizer
• Abbott
• Allergan
• TEVA
• Mylan
• Novartis
• Merck